Credit Trends: U.S. Composite Credit Spreads Daily (Oct. 3, 2011) Oct 11

  • ID: 1928419
  • October 2011
  • Region: United States
  • Standard & Poors
1 of 2

Standard & Poor's speculative-grade composite spread expanded by 13 basis points (bps) on Friday to 781 bps, and the investment-grade composite spread expanded by 1 bp to 227 bps. By rating, the 'AA' spread remained flat at 159 bps, 'A' narrowed by 1 bp to 202 bps, and 'BBB' widened by 1 bp to 279 bps. The 'BB' spread expanded by 10 bps to 560 bps, 'B' widened by 13 bps to 819 bps, and 'CCC' widened by 21 bps to 1,229 bps. By industry, financial institutions and industrials expanded by 2 bps each, to 358 bps and 361 bps, respectively. Banks widened by 5 bps to 387 bps, telecommunications expanded by 4 bps to 389 bps, and utilities remained...

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research Type: Commentary
Criteria articles describe the thought process and methodology Standard & Poor's analysts use in determining ratings. These commentary pieces discuss both the quantitative (economic and financial) and qualitative (business analysis and caliber of management) aspects of the analysis, as well as legal issues.

Note: Product cover images may vary from those shown
2 of 2
Note: Product cover images may vary from those shown


  • Quick Help: This Credit Rating Report will be emailed to you.


If you have a more general question about our products please try our



Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.